

FY 2007 - 08

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our company, nor our directors, nor any of their respective affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.



Announcing the Fusion of Biocon and AxiCorp

Biocon acquires 70% controlling stake in German Pharma company AxiCorp GmbH

- **Biocon is close to completing the acquisition of 70% stake in German pharmaceutical company, AxiCorp GmbH for a consideration of €30 Million.**
- **For marketing and distribution of a range of pharmaceuticals including generics, biosimilars, biologics and innovative pharmaceutical products in Germany and Europe.**



Biocon acquires 70% controlling stake in German Pharma company AxiCorp GmbH

- **AxiCorp is a specialized marketing and distribution company established in 2002 by a group of industry experts to address the lucrative generics and parallel distribution market in Germany and Europe.**
- **AxiCorp is ISO 9001 certified with a differentiated distribution model that is aligned to the radically altered way the German pharmaceutical market now functions.**



Biocon commences Phase IIa Clinical Trials for IN105

- **Open label, multi-centric, placebo controlled, single ascending dose study commenced**
- **Designed to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of IN105 under fed conditions in type II diabetic patients currently on Metformin therapy at 5 investigation sites.**
- **The study is expected to be completed in August 2008 and will provide the data necessary to commence Phase IIb clinical trials.**



Biocon commences Phase

IIb trials for T1h for RA & Psoriasis

- **Randomized, Open label, Four Arms Parallel Phase II Clinical Study to evaluate the Safety and Efficacy of anti-CD6 monoclonal antibody**
- **(T1h mAb) in combination with Methotrexate in Patients with Active Rheumatoid Arthritis has been initiated at 7 investigation sites.**
- **Phase II clinical trial to evaluate the Safety, Efficacy and Pharmacokinetics of anti-CD6 monoclonal antibody (T1h mAb) in Patients with Active Psoriasis is due to commence at 5 investigation sites.**



Biocon commences Phase IIb trials for T1h for RA & Psoriasis

- **Designed as a single blind, randomized, multiple dose, multiple schedule, multi-centric, parallel study in patients with active moderate to severe Psoriasis, with independent blinded disease activity assessment, and quality of life metrics assessment.**
- **These clinical trials will enable Biocon to establish Proof of Concept for T1h and will add tremendous value to its licensing potential.**



Biocon commences Phase IIb trials for Glioma and NSCLC for BIOMAb EGFR™

- **Open label, prospective, multi-centric study to evaluate the Safety And Efficacy of BIOMAb EGFR™ (Nimotuzumab)**
- **Induction and Maintenance Therapy in combination with Radiotherapy plus Temozolomide (Concomitant & Adjuvant) in Indian patients with Glioblastoma Multiforme is ongoing at 8 investigational sites across the country.**



Biocon commences Phase IIb trials for Glioma and NSCLC for BIOMAb EGFR™

- **Another open-label, randomized, comparative, multi-centric Study to assess Safety And Efficacy Of BIOMAb EGFR™ (Nimotuzumab) in Combination with Chemotherapy Versus Chemotherapy alone in the treatment of Patients with Stage IIIB / IV Non Small Cell Lung Cancer (NSCLC) is also being initiated at 11 sites.**
- **The above Clinical Trials will enable Biocon's Oncotherapeutics division to expand its market share through label extensions.**



Biocon sets up Cardiology Division

- **Cardio-Diabetes division segmented.**
- **New stand alone Cardiology division**
- **Focus on flagship statin based product Statix and other products - Telmisat, Eptifibatide and its recombinant streptokinase product Myokinase.**
- **The Cardiology market in India constitutes 10%.(Approx. 3,200 Crore) of the Indian Pharma Market and is growing at 21%.**
- **This division is envisaged to have an all India presence through a 250+ strong field force.**



Financial Highlights



Performance Highlights @



Revenues **Rs. 1,090 crs** AT **Rs. 225 crs**

FY 2008 (April '07 - March '08) v/s FY 2006 (April '06 - March '07)

- Consolidated revenue increases **19%** from Rs: **881** to Rs. **1,044** crores.
- Operating margins at **31%** . **2%** improvement
- PAT increases by **13%** to Rs. **225** crores

@ Excluding Exceptional
Net Income after Taxes of Rs. 239 crs



Performance Highlights @



Revenues **Rs. 1,090 crs** AT **Rs. 225 crs**


FY 2008 (April '07 - March '08) v/s FY 2006 (April '06 - March '07)

- R&D revenue expenditure increases by **26%** to Rs. **48** crores.
- Board recommends dividend of **100%** (Rs. 5/- per share).
- **1:1 Bonus Share issue recommended by the Board.**

@ Excluding Exceptional
Net Income after Taxes of Rs. 239 crs



Revenue (Segment wise)



P & L : FY 08 Vs FY 07

Particulars	FY - 08	% on		FY - 07	% on (Rs. Cr)
		Revenues	Revenues		
Revenues	1,090			990	
EBIDTA	335	31%		287	29%
PBT	231			211	
Tax	13			17	
PAT #	225	21%		200	20%

@ Excluding Exceptional Net Income after Taxes of Rs. 239 crs
 # after Minority interest





THANK YOU